EUVIMEDEUVIMED entdecken
Crossref

Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials

Helen Gu, Romain Sechaud, Imad Hanna, Ryan Pelis, Heidi J Einolf

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Helen Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetic Sciences, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. Electronic address: helen.gu@novartis.com. Hauptthemen laut MEDLINE: Staurosporine, Models, Biological. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Midostaurin and its active metabolites are substrates, mixed inhibitors/inducers of cytochrome P450 (CYP)3A4. The main objective of this study was to develop/refine a physiologically based pharmacokinetic (PBPK) model that incorporated recent clinical drug-drug interaction (DDI) data with midazolam after multiple dosing, to qualify the pharmacokinetic (PK) model simulations of midostaurin and its metabolites, and to apply it to predict untested clinical DDI scenarios with potential comedications. In this study, Simcyp PBPK model of midostaurin and its 2 metabolites was refined from a previously published model associated with endogenous biomarker 4β-hydroxycholesterol data through further optimization of CYP3A4 inhibition/induction potency and was qualified to simulate midostaurin steady-state PK. The incorporation of these parameters enabled DDI predictions of high midostaurin doses on the PK of midazolam and oral contraceptives containing ethinyl estradiol. Additionally, scaling factors for in vitro breast cancer resistance protein and the organic anion transporting polypeptide (OATP1B) inhibition were applied to account for the observed single-dose DDI with rosuvastatin and further extrapolated to predict steady-state DDI with other OATP1B drug substrates. The overall prediction results showed minimal impact of midostaurin at high doses on CYP3A substrates or an effect on the exposure of OATP1B substrates. In summary, the midostaurin PBPK model was retrospectively refined, requalified, and used to simulate the steady-state perpetrator DDI of midostaurin and its metabolites. This PBPK modeling approach and the resulting model predictions were implemented into the midostaurin product label (up to 100 mg twice a day) without the need for confirmatory clinical studies. SIGNIFICANCE STATEMENT: The manuscript describes how a midostaurin PBPK model was updated, verified, and applied to untested scenarios by a predict-learn-confirm cycle as new clinical data become available. It also provides a learning experience of prospective prediction by utilizing endogenous biomarker 4β-hydroxycholesterol to evaluate a complex CYP3A4-mediated drug interaction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StaurosporineModels, BiologicalHumansDrug InteractionsCytochrome P-450 CYP3AMidazolamCytochrome P-450 CYP3A InhibitorsFemaleMaleAdultHydroxycholesterolsClinical Trials as TopicCytochrome P-450 CYP3A InducersMultidrug Resistance-Associated Protein 2Computer SimulationATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm Proteins

Stichwörter der Autor:innen

Drug interactionsMetabolitesMidostaurinPBPK modeling

Substanzen

midostaurinStaurosporineCytochrome P-450 CYP3AMidazolamCYP3A4 protein, humanCytochrome P-450 CYP3A InhibitorsHydroxycholesterolsCytochrome P-450 CYP3A InducersABCC2 protein, humanABCG2 protein, human

Autor:innen und Institutionen

  • Department of Pharmacokinetic Sciences, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. Electronic address: helen.gu@novartis.com.
  • Department of Pharmacokinetic Sciences, Novartis Pharma AG - Biomedical Research, Basel, Switzerland.
  • Department of Pharmacokinetic Sciences, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Department of Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.

Zitieren

APA

Gu, H., Sechaud, R., Hanna, I., Pelis, R., & Einolf, H. J. (2025). Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100036

Vancouver

Gu H, Sechaud R, Hanna I, Pelis R, Einolf HJ. Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100036

BibTeX
@article{Gu2025,
  author = {Gu, Helen and Sechaud, Romain and Hanna, Imad and Pelis, Ryan and Einolf, Heidi J},
  title = {Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100036}
}
Kostenlos starten →